Structure-Based Design of mTORC1 Inhibitors in Cancer Therapy

mTORC1 inhibitor

cMET

Particularly we’ve tested equiactive molar ratios between 2 drugs in various sequences of administration (RAD for 48?cLC and h for 72?h (CLCRAD) or RAD for 72?cLC and h for 48?h (RADCLC) and in co-administration for 72?h

Particularly we’ve tested equiactive molar ratios between 2 drugs in various sequences of administration (RAD for 48?cLC and h for 72?h (CLCRAD) or RAD for

September 20, 2021 by racetab4 Min Reading

cMET

﻿Particularly we’ve tested equiactive molar ratios between 2 drugs in various sequences of administration (RAD for 48?cLC and h for 72?h (CLCRAD) or RAD for 72?cLC and h for 48?h (RADCLC) and in co-administration for 72?h

Particularly we’ve tested equiactive molar ratios between 2 drugs in various sequences of administration (RAD for 48?cLC and h for 72?h (CLCRAD) or RAD for 72?cLC and h for 48?h (RADCLC) and in co-administration for 72?h